Evolocumab + Standard of Care
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Hyperlipidemia and Mixed Dyslipidemia
Conditions
Hyperlipidemia and Mixed Dyslipidemia
Trial Timeline
Apr 23, 2013 → May 31, 2018
NCT ID
NCT01854918About Evolocumab + Standard of Care
Evolocumab + Standard of Care is a phase 3 stage product being developed by Amgen for Hyperlipidemia and Mixed Dyslipidemia. The current trial status is completed. This product is registered under clinical trial identifier NCT01854918. Target conditions include Hyperlipidemia and Mixed Dyslipidemia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01854918 | Phase 3 | Completed |
Competing Products
20 competing products in Hyperlipidemia and Mixed Dyslipidemia